$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000156459018012940 Filed on May 10, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$44.05M	$8.959M
YoY Change	391.67%	-31.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.710M	$5.460M
YoY Change	4.58%	23.25%
% of Gross Profit
Research & Development	$21.48M	$13.00M
YoY Change	65.18%	42.23%
% of Gross Profit
Depreciation & Amortization	$610.0K	$530.0K
YoY Change	15.09%	23.26%
% of Gross Profit
Operating Expenses	$27.19M	$13.00M
YoY Change	109.09%	42.23%
Operating Profit		-$9.506M
YoY Change		1582.48%
Interest Expense	$1.077M	$8.000K
YoY Change	13362.5%	-27.27%
% of Operating Profit
Other Income/Expense, Net	$1.066M	$549.0K
YoY Change	94.17%	16.31%
Pretax Income	$17.93M	-$8.957M
YoY Change	-300.12%	9531.18%
Income Tax	$5.370M	$3.565M
% Of Pretax Income	29.96%
Net Earnings	$12.56M	-$5.392M
YoY Change	-332.84%	227.78%
Net Earnings / Revenue	28.5%	-60.19%
Basic Earnings Per Share	$0.65	-$0.28
Diluted Earnings Per Share	$0.61	-$0.28
COMMON SHARES
Basic Shares Outstanding	19.21M	19.05M
Diluted Shares Outstanding	20.60M	19.05M

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$256.7M	$175.6M
YoY Change	46.18%	-20.33%
Cash & Equivalents	$67.53M	$19.21M
Short-Term Investments	$189.8M	$156.4M
Other Short-Term Assets	$4.900M	$6.100M
YoY Change	-19.67%	-34.41%
Inventory
Prepaid Expenses
Receivables	$44.00M	$8.959M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$305.7M	$190.6M
YoY Change	60.4%	-21.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.616M	$8.526M
YoY Change	1.06%	10.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$32.20M	$65.30M
YoY Change	-50.69%	159.13%
Other Assets	$8.200M	$14.50M
YoY Change	-43.45%	141.67%
Total Long-Term Assets	$49.00M	$88.37M
YoY Change	-44.55%	126.99%
TOTAL ASSETS
Total Short-Term Assets	$305.7M	$190.6M
Total Long-Term Assets	$49.00M	$88.37M
Total Assets	$354.7M	$279.0M
YoY Change	27.15%	-0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.700M	$4.056M
YoY Change	15.88%	57.7%
Accrued Expenses	$7.000M	$5.098M
YoY Change	37.31%	93.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$100.0K
YoY Change		0.0%
Total Short-Term Liabilities	$17.12M	$9.154M
YoY Change	86.99%	-23.64%
LONG-TERM LIABILITIES
Long-Term Debt	$1.900M	$600.0K
YoY Change	216.67%	-14.29%
Other Long-Term Liabilities	$2.300M	$2.355M
YoY Change	-2.34%	29.9%
Total Long-Term Liabilities	$4.200M	$2.355M
YoY Change	78.34%	29.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.12M	$9.154M
Total Long-Term Liabilities	$4.200M	$2.355M
Total Liabilities	$21.30M	$12.95M
YoY Change	64.52%	-14.71%
SHAREHOLDERS EQUITY
Retained Earnings		$17.27M
YoY Change		-43.41%
Common Stock		$248.8M
YoY Change		5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$333.4M	$266.0M
YoY Change
Total Liabilities & Shareholders Equity	$354.7M	$279.0M
YoY Change	27.15%	-0.94%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$12.56M	-$5.392M
YoY Change	-332.84%	227.78%
Depreciation, Depletion And Amortization	$610.0K	$530.0K
YoY Change	15.09%	23.26%
Cash From Operating Activities	-$7.580M	-$3.010M
YoY Change	151.83%	-129.92%
INVESTING ACTIVITIES
Capital Expenditures	-$760.0K	-$580.0K
YoY Change	31.03%	-61.59%
Acquisitions
YoY Change
Other Investing Activities	$7.210M	$2.380M
YoY Change	202.94%	124.53%
Cash From Investing Activities	$6.460M	$1.800M
YoY Change	258.89%	-491.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	-210.0K
YoY Change	-95.24%	-139.62%
NET CHANGE
Cash From Operating Activities	-7.580M	-3.010M
Cash From Investing Activities	6.460M	1.800M
Cash From Financing Activities	-10.00K	-210.0K
Net Change In Cash	-1.130M	-1.420M
YoY Change	-20.42%	-114.02%
FREE CASH FLOW
Cash From Operating Activities	-$7.580M	-$3.010M
Capital Expenditures	-$760.0K	-$580.0K
Free Cash Flow	-$6.820M	-$2.430M
YoY Change	180.66%	-121.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Royalty Revenue RoyaltyRevenue	19376000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	84000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1101000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	41000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15479000
	us-gaap	Net Income Loss NetIncomeLoss	24248000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33435000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19042000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19042000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-127000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-127000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10499000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-76000
	us-gaap	Share Based Compensation ShareBasedCompensation	7710000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2791000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	1984000
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	243000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-110000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1369000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3114000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	565000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	688000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-939000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	562000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5902000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	236000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3169000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	143000
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5107000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5392000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17925000
CY2018Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32186000
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17117000
CY2017Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	70038000
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8616000
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8049000
CY2018Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5380000
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5370000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3565000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	33262000
CY2018Q1	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	2944000
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12219000
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-128000
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1996000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20256000
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-23000
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1077000
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	564000
CY2017Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-15000
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8957000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9014000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	12555000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-682000
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-336000
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-23000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-682000
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5415000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23566000
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-13000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-235000
	us-gaap	Share Based Compensation ShareBasedCompensation	6759000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1021000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5437000
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	857000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-406000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3882000
CY2017Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	9298000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20982000
CY2017Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	807000
CY2017Q3	enta	Non Convertible Preferred Stock Liabilities NonConvertiblePreferredStockLiabilities	762000
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2410000
CY2017Q3	us-gaap	Liabilities Liabilities	24961000
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	191000
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	256241000
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-112000
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	45356000
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	301676000
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	326637000
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19120000
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19120000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	349000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1531000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	151273000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	36000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	202000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2634000
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19211000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1022000
CY2018Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1528000
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1256000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	99721000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	104986000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	155475000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4009000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2671000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2207000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	39000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1757000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	411000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-180000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1251000
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16577000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	9883000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, <font style="Background-color:#FFFFFF;">management’s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; valuation of stock-based awards; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. </font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates<font style="color:#000000;">.</font></p></div>
CY2018Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	273515000
	invest	Investment Warrants Expiration Date InvestmentWarrantsExpirationDate	2017-10-04
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	223079000
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1096000
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	221983000
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	228211000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	188000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	37821000
CY2017Q3	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	3156000
CY2018Q1	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	1492000
CY2017Q3	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	1130000
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1431000
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2829000
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	748000
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	456000
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	426000
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	399000
CY2018Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1439000
CY2017Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1175000
CY2018Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	632000
CY2017Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	676000
CY2018Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	337000
CY2017Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	379000
CY2018Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	199000
CY2017Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	180000
CY2017Q3	enta	Warrants Outstanding And Exercisable WarrantsOutstandingAndExercisable	1030000
	enta	Warrants Exercised WarrantsExercised	978000
	enta	Warrants Expired WarrantsExpired	52000
CY2017Q3	enta	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	0.01
	enta	Warrants Exercised Weighted Average Exercise Price WarrantsExercisedWeightedAverageExercisePrice	0.01
	enta	Warrants Expired Weighted Average Exercise Price WarrantsExpiredWeightedAverageExercisePrice	0.01
CY2018Q1	enta	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	0.01
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2298000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	536000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	94000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	24000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2716000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1517000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	52.47
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	23.39
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.44
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.89
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.08
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	125041000
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	77113000
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3590000
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3492000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7710000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6759000
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	33320000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1395000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1089000
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46000
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2529000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	449000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.271
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.330
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1439000
CY2017Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1175000
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2022-09-30
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1013000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1013000
CY2018Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	608000
CY2017Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	608000
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	598000

Files In Submission

Name	View Source	Status
0001564590-18-012940-index-headers.html	Edgar Link	pending
0001564590-18-012940-index.html	Edgar Link	pending
0001564590-18-012940.txt	Edgar Link	pending
0001564590-18-012940-xbrl.zip	Edgar Link	pending
enta-10q_20180331.htm	Edgar Link	pending
enta-20180331.xml	Edgar Link	completed
enta-20180331.xsd	Edgar Link	pending
enta-20180331_cal.xml	Edgar Link	unprocessable
enta-20180331_def.xml	Edgar Link	unprocessable
enta-20180331_lab.xml	Edgar Link	unprocessable
enta-20180331_pre.xml	Edgar Link	unprocessable
enta-ex311_6.htm	Edgar Link	pending
enta-ex312_7.htm	Edgar Link	pending
enta-ex321_8.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g201805091205301242921.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2018 Q1 Form 10-Q Financial Statement

#000156459018012940 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2018 Q1 Form 10-Q Financial Statement

#000156459018012940 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta